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One feature of neuropathic pain is a reduced
GABAergic inhibitory function. Nociceptors have
been suggested to play a key role in this process.
However, the mechanisms behind nociceptor-medi-
atedmodulationofGABAsignaling remain tobeeluci-
dated. Here we describe the identification of GINIP,
a Gai-interacting protein expressed in two distinct
subsets of nonpeptidergic nociceptors. GINIP null
mice develop a selective and prolonged mechanical
hypersensitivity in models of inflammation and neu-
ropathy. GINIP null mice show impaired respon-
siveness to GABAB, but not to delta or mu opioid
receptor agonist-mediated analgesia specifically in
the spared nerve injury (SNI) model. Consistently,
GINIP-deficient dorsal rootganglia neurons had lower
baclofen-evoked inhibition of high-voltage-activated
calcium channels and a defective presynaptic inhibi-
tion of lamina IIi interneurons. These results further
support the role of unmyelinated C fibers in injury-
induced modulation of spinal GABAergic inhibition
and identify GINIP as a key modulator of peripherally
evoked GABAB-receptors signaling.
INTRODUCTION
Peripheral nerve injury leading to chronic pain is one of the most
challenging types of pain to manage. Chronic pain is associatedwith a marked imbalance between excitatory and inhibitory
neurotransmission in the dorsal horn of the spinal cord, leading
to a state of persistent pain. In these conditions, pain arises
spontaneously, noxious stimuli evoke an exaggerated and pro-
longed response (hyperalgesia), and innocuous stimuli become
painful (allodynia) (Latremoliere andWoolf, 2009). Recent studies
using a combination of genetic and pharmacological neuronal
ablation have shown that nociceptive neurons play a pivotal
role in pain sensation in a modality-specific manner (Abraham-
sen et al., 2008; Cavanaugh et al., 2009; Han et al., 2013; Li
et al., 2011; Scherrer et al., 2009; Shields et al., 2010; Vrontou
et al., 2013). Nociceptive neurons represent amajor site of action
for pain killer therapies, as most analgesic drugs (i.e., opioids,
cannabinoids, and GABA derivatives) are known to influence
nociceptive terminals (Agarwal et al., 2007; Janson and Stein,
2003; Scherrer et al., 2009; Takeda et al., 2004). Together, these
arguments suggest that an efficient treatment of pain requires an
extensive understanding of nociceptive neuronal physiology as
well as the mechanisms that operate under pathological condi-
tions to perpetuate pain perception. Furthermore, targeting pain-
killer drugs to primary nociceptive neurons might be particularly
advantageous as they would bypass side effects related to
central activity.
The heterotrimeric G protein-coupled receptors (GPCRs)
represent the largest and most diverse family of cell surface
receptors. Their cellular localization and mode of action make
them the most targeted receptors for pain therapy. Among
these, GABAB receptors (GABAB-Rs) are of particular interest.
GABAB-Rs are found at both excitatory and inhibitory synapses
in the brain (Remondes and Schuman, 2003) as well as in the
superficial dorsal horn, predominantly on afferent terminals of
sensory neurons (Castro et al., 2004; Charles et al., 2001; EngleNeuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc. 123
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et al., 1987; Towers et al., 2000; Yang et al., 2001). Multiple lines
of evidence support an analgesic role for GABAB-Rs in animal
models of acute and chronic pain. Mutant mice lacking GABAB
receptors exhibit exaggerated responses to acute thermal and
mechanical stimuli (Gassmann et al., 2004; Schuler et al.,
2001). Baclofen, a selective agonist of GABAB-Rs, produces effi-
cient analgesia in different settings of nerve injury (Hwang and
Yaksh, 1997; Patel et al., 2001; Smith et al., 1994) and signifi-
cantly suppresses the first and second phases of formalin-
evoked pain (Dirig and Yaksh, 1995; Patel et al., 2001) but
has no effect on Complete Freund’s adjuvant (CFA)-induced
mechanical hyperalgesia (Hwang and Yaksh, 1997; Smith
et al., 1994). Peripheral baclofen-mediated analgesia is caused
by a strong inhibition of L-glutamate release from primary
afferent terminals, namely the C-unmyelinated fibers (Ataka
et al., 2000; Iyadomi et al., 2000) and a significant reduction of
GABA and glycine release in the spinal dorsal horn (Iyadomi
et al., 2000; Wang et al., 2007). Moreover, several studies have
demonstrated an impairment of GABAergic inhibition in the dor-
sal horn of the spinal cord in several nerve injury models, such as
chronic constriction injury of the sciatic nerve (CCI) and spared
nerve injury (SNI) (Engle et al., 2012; Ibuki et al., 1997; Laffray
et al., 2012; Moore et al., 2002), suggesting that spinal
GABAergic inhibition is abnormal in neuropathic pain states.
Whether primary sensory neurons are involved in this impairment
of GABAergic signaling in pathological conditions remains under
intense investigation.
Here we describe the identification of GINIP, a plant homeodo-
main (PHD) and EF-hand containing protein that preferentially
interacts with Ga inhibitory proteins. GINIP is expressed in two
distinct subsets of nonpeptidergic nociceptors: the cutaneous
free nerve ending MRGPRD-expressing neurons and TAFA4-
expressing C-low threshold mechanoreceptors (C-LTMRs) (Del-
fini et al., 2013; Li et al., 2011; Seal et al., 2009; Zylka et al.,
2005). GINIP null mice exhibit prolongedmechanical hypersensi-
tivity in models of inflammation and neuropathy without affecting
thermal hyperalgesia. Importantly, GINIP null mice selectively
resist reversal of SNI-evoked mechanical hyperalgesia by baclo-
fen, but not by delta ormu opioid receptor agonists. Consistently,
GINIP-deficient dorsal root ganglia (DRG) neurons display signif-
icantly lowerbaclofen-evoked inhibitionof high-voltage-activated
calcium channels that resulted in a defective baclofen-induced
presynaptic inhibition of lamina IIi spinal cord interneurons.
RESULTS
Identification of GINIP, a Gai-Interacting Protein
In an attempt to increase the repertoire of markers defining
discrete subsets of primary nociceptive neurons,weusedAffime-
trix microarrays to compare global gene expression profiles of
DRG of wild-type and trkAtrkC/trkC knockin mice at birth (Moqrich
et al., 2004; Leghaetal., 2010).Among theseveral hundredpoten-
tial markers identified,mkiaa1045 namedGINIP (forGa inhibitory
interacting protein) encodes a highly conserved vertebrate 400
amino acid protein of unknown function (Figure 1A). SMART pro-
gram analysis showed that GINIP is endowed with two functional
domains:aplanthomeodomain (PHD) zincfinger and twoputative124 Neuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc.EF hand domains. In order to assign a potential function to GINIP,
we launched a yeast two-hybrid assay using the full-length GINIP
as bait to screen an adult mouse brain cDNA library. Out of 134
million interactions tested, we identified 83 potential protein-pro-
tein interactions. Out of the 83 interactions, 44 containedGai1 en-
codedby11 independent clones, 38containedGai3 encodedby6
independent clones, and 1 clone encoded a non-ATPase subunit
of the proteasomePsmd11. As our yeast two-hybrid screen used
a mouse brain cDNA library, we first checked the expression
pattern of the three Gai genes (gnai1, gnai2, and gnai3) in DRG
neurons. In situ hybridizationwith a probe specific to endogenous
gnai1, gnai2, and gnai3, followed by immunofluorescent labeling
with a newly generated rat anti-GINIP antibody, demonstrated
that Gai1 is predominantly expressed in large-diameter neurons
and largely excluded from GINIP+ neurons (12.8% ± 0.16%
ofGINIP+neuronsexpressGai1, and14.5%±0.18%ofGai1
+ neu-
rons express GINIP), whereas Gai2 and Gai3 were mainly ex-
pressed in smaller-diameter neurons and showed a significant
overlap with GINIP+ neurons (55.1% ± 0.17% and 44% ± 0.15%
of GINIP+ neurons express Gai2 and Gai3, respectively, and
48.5% ± 0.11% of Gai2
+ and 54% ± 0.15% of Gai3
+ neurons
express GINIP) (Figure 1B).
To validate interactions of GINIP with the three known Gai
proteins, a glutathione S-transferase (GST) pull-down assay
was performed using GST-GINIP and human embryonic kidney
293T (HEK293T) cell extracts. The three Gai proteins were fused
to Venus protein and expressed in HEK293T cells as wild-type,
a constitutively inactive GDP-boundmutant (G203A), or a consti-
tutively active GTP-bound mutant (Q204L). Western blot using
anti-GFP antibody to detect Venus-tagged proteins showed
that GINIP interacts only with the constitutively active form of
all Gai proteins, but not with their respective wild-type or GDP-
bound forms (Figure 1C and data not shown). Very interestingly,
therewas no interaction betweenGINIP and s, q, or o types of Ga
subunits, indicating that GINIP exclusively participates in down-
stream signaling triggered by activation of Gai proteins.
GINIP Defines Two Distinct Subsets of Nonpeptidergic
Primary Sensory Neurons
To characterize the population of neurons expressing GINIP, we
performed double fluorescent labeling experiments, using rat
anti-GINIP antibody (see Figure 2A for specificity) in combination
with a variety of subtype-specific markers of adult DRG neurons.
GINIP is excluded from TrkA+, TrkB+, and TrkC+ neurons and
labels a subset of small-diameter Ret+ neurons, namely those
expressingGFRa2 (Figure 2A). Furthermolecular characterization
showed that GINIP+ neurons can be split into GINIP+/IB4+ neu-
rons (72.3% ± 0.8%, n = 3) and GINIP+/IB4– neurons (27.7% ±
0.4%, n = 3) (Figure 2A). Interestingly, GINIP+/IB4+ neurons
express mrgprD, whereas GINIP+/IB4– neurons express TH and
tafa4, two previously identified markers of C-LTMRs (Figure 2A
and data not shown) (Delfini et al., 2013; Li et al., 2011). GINIP
was excluded from TRPV1+, trpm8+, mrgprA1+, and mrgprB4+
neurons, aswell as from the subpopulation of neurons expressing
high levels of trpa1, and showed a partial overlap withmrgprA3+
neurons (Figure S1, available online). In line with its expression
profile, GINIP-expressing afferents selectively target lamina II
(PKCg+ and IB4+), but not lamina I (CGRP+), layers of the dorsal
Figure 1. GINIP, a Highly Conserved Protein, Specifically Interacts with GTP-Bound Forms of Gai
(A) Alignment of amino acid sequences of GINIP from various vertebrate species. Residues shaded in black are identical in >85%of the predicted proteins; similar
residues are highlighted in gray. The predicted PHD zinc finger (dotted box), the two EF-hand domains (#1 and #2; black lines), and the core domain of each
EF-hand (gray box) are indicated. The sequence corresponding to the spliced exon in mouse is indicated by a double line. Phosphorylated residues identified by
large-scale proteomic studies are indicated by asterisks (http://www.phosphosite.org/). Schematic representation of GINIP architecture is drawn on the bottom.
(B) In situ hybridization of DRGs with gnai1, gnai2, and gnai3 antisense probes followed by immunostaining using rat anti-GINIP antibody. gnai1 is mainly ex-
pressed in large neurons and excluded from GINIP+ population, whereas gnai2 and gnai3 were mainly coexpressed with GINIP in smaller-diameter neurons.
Scale bar, 100 mm.
(C) GST pull-down experiments: GST-GINIP (lanes 3 and 6) or GST alone (lanes 2 and 5) was incubated with lysate from HEK293 cells transfected with WT (lanes
1–3) or constitutively active forms (lanes 4–6) of Gai1, Gai2, Gai3, Gao, Gaolf, Gaq, andGas. All forms are fused with Venus protein. One-twentieth of the incubated
volume of lysate was loaded in lanes 1 and 4. Western blot performed with anti-GFP antibody shows a specific interaction of GINIP with the active forms of only
the three Gai variants.
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pressed in spinal cord neurons (Figures 2B and2C). Together, our
expression data show that GINIP defines two distinct subpopula-
tions of nonpeptidergic neurons: the cutaneous free nerve ending
MRGPRD-expressing neurons and C-LTMRs.
GINIP Is Dispensable for Developmental Specification of
GINIP-Expressing Neurons
To gain insights into the role of GINIP in the development, matu-
ration, and function of GINIP+ neurons, we generated a knockinmouse model where the ginip locus has been manipulated to
trigger ginip gene inactivation and enables genetic marking
and tissue-specific neuronal ablation of GINIP-expressing neu-
rons (Figure S2A). In this study, we focus on the GINIP loss-of-
function phenotype. GINIPflx/+ mice were crossed with mice
driving CRE recombinase in a ubiquitous manner (Schwenk
et al., 1995) to produce GINIP+/mcherry mice. GINIP+/mcherry
mice were then intercrossed to generate GINIPmcherry/mcherry
and wild-type littermates (hereafter GINIP–/– and WT mice,
respectively). GINIP–/– mice were viable and fertile, born in aNeuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc. 125
Figure 2. GINIP Defines a Subset of Nonpeptidergic Nociceptors that Targets Lamina II
(A) Characterization of GINIP-positive population in DRGs. Double immunostaining using rat anti-GINIP antibody associated with rabbit anti-TrkA or goat
anti-cRet or goat anti-TrkC antibodies or Alexa 565-conjugated isolectin-B4. In situ hybridization using antisense probes for ginip, trkB, or gfra2 followed by
immunostaining using rat anti-GINIP antibody. Double in situ hybridization usingmrgprD and tafa4 antisense probes followed by immunostaining using rat anti-
GINIP antibody. The GINIP population can be divided into two subpopulations: mrgprD+ and tafa4+ neurons. Scale bar, 100 mm.
(B) Triple immunostaining using rat anti-GINIP and rabbit anti-PKCg antibodies in combination with Alexa 488-conjugated isolectin-B4 on spinal cord sections.
(C) Triple immunostaining using rat anti-GINIP, rabbit anti-CGRP antibodies, and Alexa 488-conjugated isolectin-B4. ColabeledGINIP/IB4 fibers innervate lamina
IIo. GINIP+/IB4 fibers target lamina IIi PKCg+ interneurons. Lamina I (CGRP staining) is devoid of GINIP staining. Scale bar, 100 mm. See also Figure S1.
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mates. Immunolabeling using anti-GINIP antibody showed that
GINIP protein was completely eliminated in GINIP–/– mice (Fig-
ure S2B). Thorough quantitative and qualitative analysis of
different DRG neuronal subpopulations in adult GINIP–/– mice
revealed no difference between WT and GINIP–/– mice. Using
SCG10 as a pan-neuronal marker, we showed that DRG
neuronal counts of GINIP–/– and WT mice were similar (Fig-
ure S2C). Consistently, quantification of TrkA+, TrkB+, TrkC+,
and Ret+ neurons showed no difference between GINIP–/– and
WTDRG, and the total number ofmrgprD+, IB4+, and gfra2+ neu-
rons in L5 neurons was indistinguishable between GINIP–/– and
WT mice (Figure S2C). Together, these results suggest that
GINIP is dispensable for the developmental specification of126 Neuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc.DRG neurons, including the neuronal class expressing this
PHD and EF-hand containing protein.
GINIP Null Mice Exhibit Selective and Prolonged Injury-
Induced Mechanical Hypersensitivity
To gain insights into the functional role of GINIP in GINIP+ neu-
rons, we subjected GINIP–/– mice to a large battery of somato-
sensory tests under acute and tissue or nerve injury conditions.
GINIP–/– mice appeared normal in body weight, open-field, and
rotarod profiles, demonstrating that GINIP–/– mice do not have
abnormalities in motor activity or anxiety (Figures S3A and S3B
and data not shown). We then subjected GINIP–/– mice to a
variety of thermal tests, including the thermotaxis gradient
assay, hot and cold plate, and Hargreaves tests. In all these
Figure 3. GINIP–/– Mice Exhibit Prolonged Mechanical Pain in Carrageenan and Chronic Constriction Mouse Model
(A) Nocifensive behavior of WT and GINIP–/– mice in response to 2% formalin injection in hind paw (n = 9 and n = 8, respectively). Both genotypes exhibited the
same nociceptive duration during the first and second phase. Note that the second phase appears earlier in GINIP–/– compared to their WT littermates.
(B) Time course analysis of mechanical threshold of WT andGINIP–/– mice (n = 6 and n = 9, respectively) after 1%Carrageenan injection. GINIP–/– mice developed
a prolonged mechanical pain in Carrageenan model compared to WT littermates (***p < 0.001).
(C) Time course presenting mechanical sensitivity following CCI of GINIP–/– mice (n = 11) and WT littermates (n = 8) using three different filaments of increasing
calibers (0.07, 0.6, and 1.4 g). Baselines were determined before, and measures were performed every 5 days after CCI. WT and GINIP–/– mice developed
characteristicmechanical hypersensitivity of CCImodel. However, pain is prolonged in GINIP–/– mice and lasted during the whole 30-day trial. See also Figure S3.
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mice and their WT littermates (Figures S3C–S3F), suggesting
that GINIP is dispensable for acute and injury-induced tempera-
ture sensation. To test the ability of GINIP–/– mice to sense chem-
ical pain, we used the formalin test. Intraplantar injection of 10 ml
of 2% formalin triggered a robust first pain response in both
genotypes, but the appearance of the second pain response
occurred much earlier in GINIP–/– compared to control litter-
mates. However, when the total time spent in flinching, biting,
and licking behavior was scored, we found no significant differ-
ence between the two genotypes during the first and the second
phase (Figure 3A).We then testedGINIP–/– mice for their ability to
sense mechanical stimuli under inflammatory and neuropathic
pain conditions. In both paradigms, acute mechanical sensation
was unaffected in GINIP–/– mice (Figures 3B and 3C). In the
Carrageenan model, both genotypes developed massive me-
chanical hypersensitivity that started at 1 hr postinjection and
reached its maximal effect between 6 and 24 hr postinflamma-
tion. Carrageenan-inducedmechanical hypersensitivity returned
to baseline levels at day 3 postinflammation inWTmice, whereas
it persisted in GINIP–/– mice at this time point. Mechanical sensi-
tivity of GINIP–/– mice returned to baseline levels only 7 days
postinflammation (Figure 3B). In the chronic constriction injury
(CCI) model using the 2 3 5 stimulations with increasing mono-
filaments method (Delfini et al., 2013; Descoeur et al., 2011), WT
mice developed prototypical mechanical hypersensitivity duringthe first 2 weeks, which returned to baseline levels in the
following 2 weeks. In GINIP–/– mice, CCI-induced mechanical
hypersensitivity persisted during the 30 days trial, with all tested
monofilaments (Figure 3C), suggesting that GINIP is predomi-
nantly required for modulation of tissue injury-induced mechan-
ical hypersensitivity.
Baclofen-Mediated Analgesia following Nerve Injury Is
Impaired in GINIP–/– Mice
What are the mechanisms behind the prolonged injury-induced
mechanical hypersensitivity observed inGINIP–/–mice?Knowing
that GINIP specifically interacts with Gai proteins, we tested the
ability of GINIP–/– mice to respond to the analgesic effect of three
GPCR selective agonists: SNC-80 for the delta opioid receptor
(DOR), DAMGO for the mu opioid receptor (MOR), and baclofen
for metabotropic GABAB receptors (GABAB-Rs). These agonists
were tested under inflammatory and neuropathic pain. To model
inflammatory pain, Carrageenan was injected in the hind paw of
the mice, and to model neuropathic pain, we used the spared
nerve injury model (Decosterd and Woolf, 2000) (Figure 4). At
1 day after Carrageenan injection, WT and GINIP–/– mice ex-
hibited similar pronounced mechanical hypersensitivity (Figures
4A–4C). In agreement with a previous study (Smith et al., 1994),
intrathecal injection (IT) of baclofen had no analgesic effect
on either genotype (Figure 4A). However, administration of
SNC80 strongly reversed Carrageenan-induced mechanicalNeuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc. 127
Figure 4. Baclofen-Mediated Analgesia following Nerve Injury Is Impaired in GINIP–/– Mice
(A–C) Mechanical responses of WT and GINIP–/– mice following 1% Carrageenan injection and IT injection of 0.1 mg of baclofen (A), 10 nmol of SNC80 (B), or
0.2 nmol of DAMGO (C). Injection of baclofen has no effect on mechanical hypersensitivity, whereas SNC80 or DAMGO reversed mechanical hypersensitivity in
both genotypes (n = 6 for WT and n = 9 for GINIP–/–) (*p < 0.05; ***p < 0.001).
(D–F) Mechanical responses of WT and GINIP–/– mice following SNI and IT injection of 0.1 mg of baclofen (D), 10 nmol of SNC80 (E), or 0.2 nmol of DAMGO (F).
Injection of baclofen reversed mechanical hypersensitivity in WT mice, but not in GINIP–/– mice (n = 11 for both genotypes). Injection of SNC80 or DAMGO
reversed mechanical hypersensitivity in both genotypes (n = 7 for GINIP–/– and n = 8 for WT) (**p < 0.01; ***p < 0.001).
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reduced, though significant, reversal of mechanical hypersensi-
tivity both in WT and GINIP–/– mice (Figure 4C). In the SNI model,
WT and GINIP–/– mice showed a profound and long-lasting
mechanical hypersensitivity of the partially denervated hind
paw (Figures 4D–4F). Importantly, IT injection of baclofen
strongly reversed the mechanical hypersensitivity produced by
nerve injury in WT mice but had no effect on GINIP–/– mice (Fig-
ure 4D). However, administration of SNC80 and DAMGO signifi-
cantly decreased themechanical hypersensitivity in bothWT and
GINIP–/– mice (Figures 4E and 4F), demonstrating that GINIP is
selectively required for GABAB-Rs-mediated, but not MOR- or
DOR-mediated, analgesia in the neuropathic pain model used
in this study.
Baclofen-Evoked Inhibition of HVA Ca2+ Channel Is
Defective in GINIP-Deficient DRG Neurons
It is well described that most Gai/o-coupled GPCRs pro-
duce analgesia by controlling multiple downstream effectors,
including inhibition of high-voltage-activated (HVA) Ca2+ chan-
nels to reduce neurotransmitter release from afferent and spinal
neurons (Tatebayashi and Ogata, 1992), activation of inwardly
rectifying K+ channels to reduce excitability of pre- and postsyn-
aptic spinal neurons (Takeda et al., 2004), and Gai/o-mediated in-
hibition of adenylyl cyclase to reduce cyclic AMP (cAMP) levels
to counteract protein kinase A (PKA) activity (Tedford and Zam-128 Neuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc.poni, 2006). Among these mechanisms, inhibition of presynaptic
N-type HVA calcium channels has been described to play a
prominent role in this process (Nockemann et al., 2013; Tedford
and Zamponi, 2006). Thus, to address whether GINIP modulates
GPCR signaling, we explored receptor-mediated inhibition of
HVA Ca2+ channels in GINIP-expressing DRG neurons by taking
advantage of the expression of themcherry protein from ginip lo-
cus (Figure S2A). Using patch-clamp whole-cell recordings, we
monitored the effects of SNC80-, DAMGO-, and baclofen-medi-
ated inhibition of HVA Ca2+ channels on cultured heterozygous
and homozygous mcherry+ neurons. SNC80 and DAMGO had
very little and similar effects on HVA Ca2+ channels of mcherry+
neurons cultured from GINIP+/– and GINIP–/– mice (Figure 5A). In
contrast, bath application of baclofen induced strong inhibition
of HVA Ca2+ channels in heterozygous neurons that was signifi-
cantly reduced in GINIP–/– neurons (Figures 5A and 5B). The
extent of baclofen-mediated inhibition of HVA Ca2+ channels in
GINIP-expressing neurons is heterogeneous, suggesting differ-
ential expression of the GABAB-Rs and/or Gbg-sensitive HVA
calcium channels in these neurons. Moreover, kinetics of baclo-
fen inhibition washout showed a significantly faster time con-
stant of current recovery in the absence of GINIP (1.68 ±
0.21 ms and 3.23 ± 0.19 ms for GINIP–/– and GINIP+/– respec-
tively, n = 10–12, p < 0.001). These data demonstrate that
baclofen-induced analgesia is impaired in GINIP–/– mice and
suggest that GABAB-Rs are highly enriched in GINIP
+ neurons,
Neuron
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rons. Indeed, double staining experiments show that MOR
is virtually excluded from GINIP+ neurons (3.2% ± 0.82%) (Fig-
ure 5C) and DOR is expressed only in a very small subset of
GINIP+ neurons (22.51% ± 2.94%) (Figure 5D), whereas virtually
all GINIP+ neurons express GABAB1 and GABAB2 receptors (Fig-
ures 5E and 5F). Taken together, our electrophysiological
and expression data reinforce and extend previous reports
showing that baclofen has a greater effect on C fiber- than Ad
fiber-evoked glutamate release in the spinal cord (Ataka et al.,
2000; Iyadomi et al., 2000) and that GINIP profoundly regulates
GABAB-induced intracellular signaling.
GINIP Also Modulates Adenylyl Cyclase Activity in
Response to Gai-Coupled Receptors
To gain mechanistic insights into GINIP mode of action, we used
an in vitro system in which we monitored the effect GINIP gain
and loss of function on two distinct effectors: Cav2.2 channel
and adenylyl cyclase in response to baclofen and DAMGO. To
test the role of GINIP in modulation of Gai-protein regulation
of Cav2.2 activity, human Cav2.2 channels were transiently ex-
pressed in tsA-201 cells along with rat b1b and a2d1b auxiliary
subunits, the human GABAB1 and GABAB1 receptors, or the rat
MOR receptor. Whole-cell barium (Ba2+) currents recordings
showed that bath application of baclofen or DAMGO induced
strong inhibition of Cav2.2 channel in the presence or absence
of GINIP. In contrast, cells overexpressing GINIP displayed a
significantly delayed time constant of current recovery from inhi-
bition in response to both agonists (Figures 6A and 6B).
To unravel the role of GINIP in modulation of G protein regula-
tion of adenylyl cyclase, we monitored intracellular cAMP level in
tsA201 cells and in DRG neuronal cultures. In tsA201 cells, we
used bioluminescence resonance energy transfer (BRET) (Barak
et al., 2008). In this experiment, tsA-201 cells were transiently
transfected with the EPAC biosensor, the human GABAB1 and
GABAB2 receptors, or the rat MOR receptor in the presence or
absence of GINIP. Following baseline measurement, cells were
stimulated with 1 mM forskolin, either alone or together with
50 mMbaclofen (Figures 6C and 6D) or 1 mMDAMGO (Figure S4).
Forskolin stimulation induced a significant decrease in the BRET
signal (red line), indicating an increase in cAMP levels. Forskolin-
triggered decrease of BRET signal was significantly attenuated
(blue line) in the presence of baclofen (Figures 6C and 6D) and
DAMGO (Figure S4), indicating a decrease in cAMP levels.
Importantly, baclofen- and DAMGO-mediated decrease of
cAMP levels was strongly inhibited in cells overexpressing GINIP
(Figures 6C, 6D, and S4), suggesting that GINIP uncouples
GABAB and MOR from cAMP signaling. In control experiments,
tsA-201 cells overexpressing GINIP alone (Figures 6C and 6D)
or along with ProKR2, a Gas-coupled receptor (Figure S4),
showed that GINIP does not modify the forskolin-mediated in-
crease of cAMP, further demonstrating the selective association
of GINIP with Gai proteins.
To further address the role of GINIP in G protein regulation of
adenylyl cyclase, wemonitored intracellular cAMP levels directly
in GINIP-expressing neurons using two-photon FRET imaging
of the cAMP FRET sensor Epac-SH150 (Polito et al., 2013).
Cultured heterozygous and homozygous GINIP+ neurons weretransduced with a recombinant Sindbis virus that allows rapid
and highly efficient expression of Epac-SH150 (Gervasi et al.,
2007; Hepp et al., 2007; Polito et al., 2013). In these conditions,
mCherry fluorescence was too weak to be detected in GINIP+
neurons. As GINIP is expressed in 95% of IB4+ neurons, we
used this isolectin to efficiently visualize GINIP-expressing neu-
rons. Expression of Epac-SH150 was observed in 32% of IB4+
neurons (52 cells out of 161). The effect of 50 mM baclofen on
cAMP levels was evaluated by comparing the amplitude and
the onset kinetics of two consecutive 1 min long bath applica-
tions of 5 mM forskolin, with baclofen being applied for 5min prior
to and during the second application of forskolin. In the absence
of baclofen, two consecutive bath applications of forskolin pro-
duced similar increases of cAMP with similar amplitudes and
onset kinetics in either genotype (data not shown). In the pres-
ence of baclofen, the mean amplitude of the second forskolin-
evoked cAMP increase was similar to that measured in control
conditions in the absence of baclofen (104% ± 4% and 97% ±
3% of control in GINIP+/– [n = 9] and GINIP–/– neurons [n = 8],
respectively) (Figures 6E and 6F). In GINIP+/– neurons, baclofen
did not affect onset kinetics of forskolin-induced response, as
the ratio of slopes between the two-response onset was 1.03 ±
0.08 (n = 9). In contrast, the onset kinetics of the forskolin-medi-
ated responsewas slower in the presence of baclofen in GINIP–/–
neurons (slope ratio baclofen/control = 0.74 ± 0.06, p < 0.05,
n = 8) (Figures 6E and 6G), indicating that loss of GINIP enhances
baclofen-mediated inhibitory effect on adenylyl cyclase.
These data are in agreement with the data obtained in tsA201
cells in which we show that overexpression of GINIP decreases
DAMGO- and baclofen-mediated inhibitory effect on adenylyl
cyclase. Together, our gain- and loss-of-function data demon-
strate that GINIP plays a prominent role in modulation of Gai-
coupled receptor signaling: it strongly interferes with the kinetics
of inhibition of HVA Ca2+ channels and slightly affects the pro-
duction of cAMP. Our data also demonstrate that GINIP can
modulate Gai signaling triggered by receptors other thanGABAB.
Baclofen-Mediated Presynaptic Inhibition Is Impaired in
GINIP–/– Mice
To further characterize the mechanisms that cause the pro-
longed injury-induced mechanical hypersensitivity and impaired
response to baclofen-induced analgesia in GINIP–/– mice, we
measured synaptic transmission between primary afferent neu-
rons and lamina II interneurons in the presence of baclofen
(10 mM), SNC80 (20 mM), and DAMGO (1 mM). We performed
whole-cell voltage clamp recordings in acute spinal cord slices
while applying a pair of high-intensity electric stimulations on
attached dorsal roots. We found that the average paired pulse
ratio of evoked EPSCs (PPR) did not differ between WT (1.04 ±
0.102, n = 10; Figures 7A1 and 7A3) and GINIP–/– mice
(0.912 ± 0.073, n = 18; Figures 7A2 and 7A3). However, following
bath superfusion of baclofen (10 mM), the PPR was significantly
increased in both WT (n = 10) and GINIP–/– (n = 18) mice (Figures
7A1–A3), indicating presynaptic inhibition of evoked response
(p < 0.001). Interestingly, in these conditions, the PPRwas signif-
icantly higher in neurons recorded from WT mice (2.12 ± 0.034)
than in neurons recorded from GINIP–/– mice (1.35 ± 0.162, p <
0.05), indicating an impaired baclofen-mediated presynapticNeuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc. 129
(legend on next page)
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Figure 6. GINIP Modulates HVA Ca2+
Channels and cAMP Levels in Response
to Baclofen
(A) Typical example of the time course of baclofen-
induced N-type barium current inhibition in tsA201
cells expressing recombinant Cav2.2 channels
andGABAB receptors in the presence (gray circles)
or absence (black circles) of GINIP-GFP. Currents
were evoked by a short 5 ms test pulse to +10 mv
from 80 mv given at 1 Hz. Note the slow termi-
nation of baclofen inhibition in the presence of
GINIP.
(B) Summary of the agonist washout kinetics for
experiments similar to (A) for GABAB or MOR re-
ceptors coexpressed with Cav2.2. The washout
time constant was normalized to the value in the
absence of GINIP (filled bars) compared to the
values in the presence of GINIP (open bars).
(C) Baclofen-induced changes in the BRET ratio
determined in tsA201 cells expressing GABAB re-
ceptors or an empty vector in the presence or
absence of GINIP. The BRET ratio decreases
during forskolin stimulation (red), and this decrease
is significantly attenuated in the presence of
baclofen (blue). Overexpression of GINIP inhibits
baclofen-mediated reduction of FSK-triggered
decrease in BRET ratio.
(D) Bar graph of the changes in BRET ratio deter-
mined in experiments as in (C).
(E) Traces show the increase in cAMP observed
with Epac-SH150 in one IB4+ neuron from GINIP
heterozygous (left) and homozygous (right) cul-
tures. The two consecutive responses to forskolin
were overlaid for comparison. The 1 min applica-
tion of 5 mM forskolin is indicated by an arrow.
Combined application of forskolin and the phos-
phodiesterase inhibitor IBMX was used to control
the sensor’s saturation.
(F) A 5 min baclofen application prior to the second
forskolin stimulation does not affect the amplitude
of the second response (left) but decreases the
onset kinetics of the response in GINIP-deficient
DRG neurons as indicated by the significantly
decreased slope ratio (right).
Data are presented as the mean ± SEM and
compared with a t test.
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average reduction in evoked EPSC amplitude was significantly
more pronounced in neurons from WT (73.4% ± 3.5%) thanFigure 5. GINIP Is Selectively Expressed in GABAB-Rs
+, but Not in MO
(A) Summary of the maximal inhibition produced by SNC80 (1 mM), DAMGO
recorded from mCherry-positive DRG neurons from either GINIP+/– (gray circle
current inhibition ± SEM. Each circle represents an individual cell tested. HVA cur
of 80 mV.
(B) Typical traces of current inhibition produced by baclofen in mCherry-positive
(C and D) Double immunostaining using anti-MOR (C) or anti-GFP (D) in combina
(E and F) In situ hybridization using antisense probes for gababr1 (E) and ga
bars, 40 mm.from GINIP–/– mice (58% ± 4.5%, p < 0.05; Figure 7A4). In
contrast, although the delta opioid agonist SNC80 (20 mM)
induced a significant increase in PPR (Figures 7B1–7B3,R+ or DOR+ Neurons
(1 mM), and baclofen (50 mM) of high-voltage-activated calcium currents
s) or GINIP–/– mice (black circles). Bars in the histogram represent the mean
rents were elicited by 20 ms long test pulses to 10 mV from a holding potential
DRG neurons from the two genotypes.
tion with rat anti-GINIP antibody.
babr2 (F), followed by immunostaining using rat anti-GINIP antibody. Scale
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Figure 7. Modulation of Synaptic Transmis-
sion in GINIP Null Mice
(A) Normalizedwhole-cell voltage clamp recordings
of EPSCs evoked by a pair of electric shock on
attached dorsal root in WT (A1) and GINIP–/– (A2)
animal lamina II neurons, in control and following
superfusion of baclofen (10 mM). (A3) Paired pulse
ratio of evoked EPSCs in control and following
baclofen bath application in WT and GINIP–/– mice.
(A4) Normalized evoked EPSC amplitude in control
and following baclofen superfusion.
(B) Normalizedwhole-cell voltage clamp recordings
of EPSCs evoked by a pair of electric shock on
attached dorsal root in WT (B1) and GINIP–/– (B2)
animal lamina II neurons, in control and following
superfusion of SNC80 (20 mM). (B3) Paired pulse
ratio of evoked EPSCs in control and following
SNC80 bath application in WT and GINIP–/– mice.
(B4) Normalized evoked EPSC amplitude in control
and following SNC80 superfusion.
(C)Normalizedwhole-cell voltageclamp recordings
of EPSCs evoked by a pair of electric shock on
attached dorsal root in WT (C1) and GINIP–/– (C2)
animal lamina II neurons, in control and following
superfusion of DAMGO (1 mM). (C3) Paired pulse
ratio of evoked EPSCs in control and following
DAMGO bath application in WT and GINIP–/– mice.
(C4) Normalized evoked EPSC amplitude in control
and following DAMGO superfusion.
Traces in A1, A2, B1, B2, C1, and C2 have been
scaled in order to facilitate the comparison of PPR
(*p < 0.05).
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differ in neurons from WT (2.01 ± 0.349, n = 10) and GINIP–/–
(1.614 ± 0.204, n = 14) spinal slices. Similarly, the reduction in
evoked EPSC amplitude caused by SNC80 superfusion was
not significantly different between WT (52.7% ± 6.1%) and
GINIP–/– (38.4% ± 7.8%) mice (Figure 7B4). Finally, the effect
of mu opioid agonist DAMGO on PPR was very similar in WT
(1.34 ± 0.15, n = 8) and GINIP–/– (1.73 ± 0.34, n = 11) spinal slices
(Figure 7B3), and no difference was observed in the reduction of
evoked EPSC amplitude between WT (38.1% ± 10.2%) and
GINIP–/– (50.5% ± 7.2%) mice (Figure 7C4). Together, our data
indicate that baclofen-induced presynaptic inhibition of synaptic
transmission between primary afferent neurons and lamina II
interneurons is impaired in GINIP–/– mice.
DISCUSSION
Peripheral nerve injury-evoked chronic pain induces complex
changes in the GABAergic system, and primary sensory neurons
have long been suggested to play a predominant role in this pro-
cess. Indeed, electrophysiological recordings on spinal cord
slices have shown that CCI and SNI models induce substantial
reduction of primary afferent-evoked inhibitory postsynaptic cur-
rents (IPScs) (Moore et al., 2002), and baclofen reduces the
amplitude of primary afferent-evoked excitatory postsynaptic
currents (EPSCs) (Ataka et al., 2000). Moreover, baclofen has a
greater effect on C fiber- than Ad fiber-evoked EPSCs, suggest-
ing that the effect of baclofen is primarily due to GABAB recep-
tors located at the terminals of C-unmyelinated nociceptors132 Neuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc.(Ataka et al., 2000). However, the molecular identities of the sub-
populations of primary sensory neurons that are affected by this
impairment of GABAergic inhibition are still unknown. In our
study, we showed that GINIP is highly enriched in a subset of un-
myelinated nonpeptidergic nociceptors that terminate within the
outer and inner parts of the lamina II layer of dorsal horn spinal
cord. Behavioral analyses showed that GINIP–/– mice exhibited
a selective and prolonged tissue injury-induced mechanical
hypersensitivity that was resistant to baclofen-mediated, but
not MOR- or DOR-mediated, analgesia. GINIP-deficient DRG
neurons displayed reduced inhibition of HVA Ca2+ channels
and a slightly delayed forsolin-evoked production of cAMP in
response to baclofen. Accordingly, baclofen-mediated presyn-
aptic inhibition of lamina IIi spinal cord interneurons was severely
impaired in GINIP–/– mice. These results provide compelling
evidence supporting the role of primary sensory neurons, namely
unmyelinated C fibers, in injury-induced modulation of spinal
GABAergic inhibition and identify GINIP as a key modulator of
peripherally evoked GABAB-Rs signaling.
How could GINIP modulate GABAB-Rs signaling? It is
well established that agonist activation of GABAB-Rs triggers
conformational changes that cause heterotrimeric G proteins
to dissociate into GTP-bound Gai and Gbg. Gai-GTP inhibits
adenylyl cyclase, and Gbg dimer inhibits Cav2 family of HVA
Ca2+ channels (Tedford and Zamponi, 2006). The net output
of GABAB-R activation is a presynaptic inhibition of excitatory
transmission in the spinal cord and reduced pain trans-
mission. We showed that GINIP preferentially interacts with
the active forms of Gai proteins. Patch-clamp recordings of
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nificant reduction of HVA Ca2+ channel activity in GINIP hetero-
zygous neurons, and this reduction was significantly reduced in
GINIP-deficient DRG neurons. Furthermore, overexpression of
GINIP in tsA-201 cells strongly inhibited Gai-evoked decrease
in cAMP levels and significantly increased the time constant
of recovery from DAMGO- and baclofen-induced inhibition
of Cav2.2 channels. Using cAMP-based FRET system, we
showed that baclofen-mediated inhibition of cAMP production
is slightly delayed, but not completely altered, in GINIP-defi-
cient DRG neurons. Consistently, electrophysiological record-
ings of lamina IIi interneurons showed that baclofen-mediated
presynaptic inhibition was severely impaired in GINIP–/– mice.
In line with these in vitro data, our behavioral experiments
showed that GINIP–/– mice were resistant to baclofen-mediated
reversal of nerve injury-induced mechanical hypersensitivity,
suggesting that GINIP/Gai-GTP interaction tightly regulates
Gai-triggered modulation of HVA Ca
2+ channels and adenylyl
cyclase activities in vivo. How can GINIP–/– mice resistance
to baclofen-mediated analgesia under neuropathic pain
condition be explained? We favor the hypothesis that GINIP in-
terferes with the kinetics of heterotrimeric G protein dissocia-
tion/association in response to baclofen. Loss of GINIP will
favor rapid conversion of Gai-GTP to Gai-GDP form, causing
rapid reassociation of Gai-GDP to Gbg proteins, leading to
rapid termination of baclofen-mediated G protein signaling.
Rapid G protein signaling termination will cause a diminished
inhibition of HVA Ca2+ channels and the maintenance of
injury-induced high levels of cAMP. Diminished baclofen-
induced inhibition of HVA Ca2+ channels in combination with
the maintenance of high levels of cAMP will shift the balance
toward increased excitability of afferent fibers and enhanced
pain transmission. In line with this hypothesis, we showed
that baclofen-mediated inhibition of HVA Ca2+ channels is
strongly altered in GINIP-deficient DRG neurons and that these
same neurons displayed a slight alteration of forskolin-medi-
ated production of cAMP in response to baclofen. Whether
HVA Ca2+ channels and adenylyl cyclase are the unique effec-
tors of GINIP/Gai interaction remains to be determined. Indeed,
G protein-coupled inwardly rectifying K+ channels, the major
type of potassium channels, are important regulators of
neuronal excitability, and their activation is tightly regulated
by Gbg proteins (Lu¨scher and Slesinger, 2010). A recent study
has shown that GIRK channels are absent in mice primary sen-
sory neurons, whereas these channels are functionally present
in rat and human DRG neurons (Nockemann et al., 2013), sug-
gesting that GINIP modulation of baclofen-mediated peripheral
analgesia might be principally controlled by the extent of inhibi-
tion of HVA Ca2+ channels and adenylyl cyclase functions
following GABAB-R activation.
Our expression data also showed that GINIP is highly en-
riched in two molecularly and functionally distinct subpopula-
tions of neurons: the cutaneous free nerve ending MRGPRD+
neurons and C-LTMRs (Delfini et al., 2013; Li et al., 2011; Seal
et al., 2009; Zylka et al., 2005). Recent studies have shown
that the former population is involved in sensing acute and
inflammation-induced mechanical stimuli (Cavanaugh et al.,
2009; Shields et al., 2010) and the latter is specialized in sensingacute gentle touch and injury-induced mechanical and chemical
pain (Abrahamsen et al., 2008; Delfini et al., 2013; Li et al., 2011;
McGlone et al., 2014; Seal et al., 2009; Zotterman, 1939).
GINIP–/– mice had normal responses to thermal stimuli under
acute and inflammatory conditions and exhibited a slightly
perturbed response in the formalin test. In this test, GINIP–/–
mice showed an early onset of formalin-evoked second pain
response, reminiscent of that observed in mice lacking the
type 4 metabotropic glutamate receptor (Vilar et al., 2013).
The major phenotype observed in GINIP–/– mice consists of a
selective and delayed mechanical hypersensitivity in the setting
of neuropathic pain. This finding further supports the modality
specificity view that argues that molecularly characterized sub-
sets of primary sensory neurons are specialized in sensing and
transducing well-defined sensory modalities (Abrahamsen et al.,
2008; Cavanaugh et al., 2009; Delfini et al., 2013; Han
et al., 2013; Seal et al., 2009; Shields et al., 2010; Vrontou
et al., 2013). Indeed, we showed that IT injection of baclofen
had no effect on Carrageenan-induced mechanical hypersensi-
tivity in both WT and GINIP–/– mice. However, baclofen strongly
reversed nerve injury-induced mechanical pain in WT, but
not in GINIP–/– mice. Impaired reversal of nerve injury-induced
mechanical pain in GINIP–/– mice was selective to baclofen,
as SNC80 and DAMGO efficiently reversed SNI-induced me-
chanical hypersensitivity in these mice. Our expression data
showed that MOR+ and GINIP+ neurons are mutually excluded
from each other and that a significant number of GINIP+ neurons
(22%) coexpress DOR. While GINIP/MOR mutual exclusion
provides a straightforward explanation of DAMGO-mediated
reversal of SNI-induced mechanical hypersensitivity in GINIP–/–
mice, the strong SNC-80 effect in these mice is somehow
puzzling. We hypothesize that SNC-80-mediated reversal
of SNI-induced mechanical hypersensitivity in GINIP–/– mice
mainly occurs through DOR activation in myelinated cutaneous
A fibers (Bardoni et al., 2014; Scherrer et al., 2009). Indeed, it
has been shown that ischemic block of myelinated axons abol-
ishes touch-evoked neuropathic pain in human (Campbell et al.,
1988). Furthermore, ablation of the vast majority of C fibers,
including the specific ablation of MRGPPD+ neurons, does not
alter nerve injury-induced mechanical hypersensitivity in mice
(Abrahamsen et al., 2008; Cavanaugh et al., 2009). In line with
this, our electrophysiological recordings showed that bath
application of SNC-80 had no or very little effect on HVA Ca2+
channels in GINIP-expressing neurons, suggesting that DOR+/
GINIP+ small-diameter neurons play a minimal role in SNC-80-
mediated analgesia in GINIP–/– mice.
Our in vitro studies revealed that GINIP can also modulate
MOR-mediated inhibition of Cav2.2 channel and adenylyl
cyclase in a similar manner to that of GABAB-Rs, arguing that
GINIP can be recruited upon activation of at least another Gai-
coupled GPCR, thus opening avenues to deepen our under-
standing of GPCR biology. For instance, it is well established
that regulators of G protein signaling (RGS proteins) play a key
role in regulating GPCR activities. RGS proteins preferentially
bind the active forms of Ga subunits and act as GTPase-acti-
vating proteins (GAPs) to accelerate (up to 1,000-fold) the rate
of Ga-GTP hydrolysis, thereby limiting their lifetime under the
active form (Hollinger and Hepler, 2002). Here we found thatNeuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc. 133
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three Gai isoforms. We also showed that overexpression of
GINIP inhibited DAMGO- and baclofen-induced decrease of
cAMP levels and that loss of GINIP strongly reduced baclofen-
induced inhibition of HVA Ca2+ channels. We hypothesize that
GINIP and RGS proteins might compete with each other to
bind Gai-GTP proteins. GINIP binding to Gai-GTP will prevent
RGS binding and blocks its GAP activity, causing a prolonged
receptor-mediated activation. On the other hand, RGS binding
to Gai-GTP will accelerate the rate of GTP hydrolysis and favors
rapid reassociation of Gai-GDP with Gbg subunits and termi-
nation of receptor-mediated activation. This hypothesis can
provide a rational explanation of GINIP–/– mice resistance to bac-
lofen-mediated analgesia, as Gai-GTP can only bind to RGS pro-
teins that will accelerate its conversion to Gai-GDP, decreasing
the length of receptor-mediated outcomes. Further dissection
of the molecular mechanisms controlling the dynamics of GINIP
and RGS proteins binding to the active forms of Gai proteins will
certainly deepen our understanding of G protein-coupled recep-
tor signaling.
In conclusion, the results presented in this study are 3-fold: (1)
they further consolidate the view of primary sensory neuron mo-
dality specificity, as we demonstrated that GINIP expression in
a subset of nonpeptidergic nociceptors is required to selectively
sense and transduce injury-induced mechanical pain; (2) they
identify GINIP as a key modulator of primary sensory neurons-
mediated regulation of the GABAergic system in the spinal cord;
and (3) they identify GINIP as amodulator of Gai-coupled GPCRs.
These findings indicate that targeting peripherally restricted Gai-
coupled receptor agonistsmightmaintain high levels of analgesic
activity while significantly decreasing their well-established side
effects. Further studies of the kinetics of GINIP modulation of
Gai-triggered signaling pathway in response to GABAB receptor
activation will deepen our understanding of the GABAergic inhib-
itory function in controlling pain transmission.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for further details.
Animals
All protocols are in agreement with European Union recommendations
for animal experimentation. See Supplemental Experimental Procedures for
a detailed description of the mice used.
In Situ Hybridization and Immunofluorescence
In situ hybridization and immunofluorescence were carried out following stan-
dard protocols (Moqrich et al., 2004). Briefly, animals were anesthetized and
then transcardially perfused with 4% paraformaldehyde in phosphate-buff-
ered saline (PBS). Then, DRGs and spinal cord were dissected, postfixed
ON in the same fixative, and cryoprotected into a sucrose solution. Samples
were sectioned at 12 mm (DRG section) or 16 mm (spinal cord section). Probes
were hybridized overnight at 55C, and the slides were incubated with
the horseradish peroxidase anti-digoxigenin/fluorescein/biotin antibodies
(Roche). Final detection was achieved using fluorescein/cy3/cy5 TSA plus
kit (Perkin Elmer). For double fluorescent in situ experiments, the first antibody
was inactivated using H2O2 treatment. For immunofluorescence, tissues sec-
tions were incubated in blocking solution for 1 hr at room temperature (RT), pri-
mary overnight at 4C, and secondary antibody for 2 hr at RT. Acquisition of
images was performed on AxioImager Z1 (Zeiss). See Supplemental Experi-
mental Procedures for further details.134 Neuron 84, 123–136, October 1, 2014 ª2014 Elsevier Inc.Electrophysiology on Isolated DRG Neurons
Lumbar DRGs with attached roots were dissected from adult GINIP heterozy-
gote and null mice and were collected in Hank’s balanced salt solution (HBSS)
medium without calcium (Invitrogen). DRGs were prepared as in Delfini et al.
(2013). Patch-clamp recordings were performed 12–28 hr after plating on
mCherry-positive cells visualizedwith the epifluorescence connected to the in-
verted Olympus IX70 microscope. For calcium current recordings, the extra-
cellular solution contained (in mM): 2 CaCl2, 100 TEACl, 2 NaCl, 1 MgCl2, 40
choline Cl, 5 glucose, 5 4AP, 0.5 mg/ml BSA (pH 7.4 with TEAOH, 330
mOsM). Pipettes with a resistance of 1–1.5 MU were filled with an internal so-
lution containing (in mM): 110 CsCl, 3 MgCl2, 10 EGTA, 10 HEPES, 3 Mg-ATP,
0.6 GTP (pH 7.4 with CsOH,300 mOsM). Drug application (DAMGO, SNC80,
and baclofen) was performed as for recombinant channels in tsA201 cells.
Electrophysiology on Spinal Cord Slices with Attached Dorsal Root
Transverse spinal cord slices with attached dorsal roots from juvenile
(P28–P44) GINIP–/– and WT mice were prepared for whole-cell recording as
described in Delfini et al. (2013). Typically, a pair of high-duration (500 ms),
high-intensity stimulations (350 mA) was used to recruit most primary afferent
fibers in the recorded slice. A total of 20 consecutive paired stimulations with
5 s intervals were averaged. Paired pulse ratio was calculated as the ratio be-
tween the amplitude of the second and the first synaptic responses. Normal-
ized synaptic responses were calculated by dividing the average response
during drug application by the average responsemeasured in control. The pro-
tocol was repeated 5 times in control and 1, 3, 5, and 7 min after drug applica-
tion (bath application for 1 min). The peak of the response (usually observed
at 1 or 3 min) was used for statistical analysis. Liquid junction potentials
(calculated value 16.5 mV) are not corrected for. SNC80 was purchased
from Tocris, and DAMGO and baclofen were purchased from Sigma-Aldrich.
SNC80 and DAMGO superfusion was achieved in the presence of 1 mM
CGP55845A in order to prevent an indirect action on paired pulse ratio through
local GABAergic interneurons. Two-way ANOVA with repeated measures
was used to compare the effects of drugs in WT and GINIP–/– mice. Student’s
t test, and signed-rank-sum test were used to compare the relative decrease in
EPSC amplitude between different GINIP+/+ and GINIP–/– mice.
Behavioral Assays
All behavioral analyses were conducted on littermate males 8–12 weeks old.
Animals were acclimated for 1 hr to their testing environment prior to all exper-
iments that were done at room temperature (22C). Student’s t test was used
for all statistical calculations. All error bars represent SEM. See Supplemental
Experimental Procedures for a detailed description of all the behavioral tests
used in this study.
Spared Nerve Injury Model of Neuropathic Pain
Spared nerve injury surgery was performed as described (Decosterd and
Woolf, 2000). Briefly, mice were anesthetized with a mix of ketamine/xylazine
while an incision wasmade through the skin and thighmuscle at the level of the
trifurcation of the sciatic nerve. The common tibial and peroneal nerve were
ligated with 6.0 silk (Ethicon) and transected, leaving the sural nerve intact.
Mechanical thresholds were determined 7 days after the surgery, before and
after drug administration, and 30 days after the surgery. Mechanical threshold
was determined using the up-down method.
Intrathecal Injections of Drugs
Animals were placed in habituation cages 1 hr prior to the administration
of drugs. A total of 10 ml of each compound was injected intrathecally in
unanesthetized mice. Successful placement of the needle was confirmed
by flick of the tail. Baclofen (Sigma-Aldrich) was dissolved in H20 solution
(pH 7.6), SNC80 (Tocris Bioscience) was dissolved in 100 mM HCl solution,
and DAMGO (Sigma-Aldrich) was dissolved in saline solution (0.9% NaCl).
Response to mechanical stimulations was recorded 15 min after drug
administration using the up-down method.
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